Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3Phase 1 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 11NIH 3NETWORK 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3

Interventions

Specimen Handling 180Cyclophosphamide 161Magnetic Resonance Spectroscopy 153Biopsy 128Radiotherapy 109Cisplatin 109Bevacizumab 107Carboplatin 101Doxorubicin 96Paclitaxel 94Etoposide 87Filgrastim 81aldesleukin 78Gemcitabine 73Vincristine 72Fluorouracil 72Leucovorin 62fludarabine phosphate 58Docetaxel 58Bortezomib 54Sorafenib 53Cytarabine 51Methotrexate 50Taxes 49Immunoglobulin G 49Disulfides 49Rituximab 48Oxaliplatin 48sargramostim 47Prednisone 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × NIH × Flutamide × Clear all
NCT00450463 2018-11-29

Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
64 enrolled 13 charts
Genitourinary

Prostatic Neoplasms

NCT00003124 2014-01-06

Hormone Therapy Plus Radiation Therapy in Treating Patients With Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
105 enrolled
Genitourinary

Prostatic Neoplasms

NCT00003517 2013-07-10

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡